Avinger (Redwood City, CA) has signed an agreement with HealthTrust (Brentwood, TN) under which members of the HealthTrust group purchasing organization will acquire Avinger's portfolio of technologies designed to treat peripheral artery disease (PAD, which increases risk of heart attack and stroke), including the Pantheris optical coherence tomography (OCT) image-guided atherectomy system that recently received FDA approval. The agreement becomes effective September 15, 2016.
Related: Avinger receives FDA approval for enhanced OCT image-guided atherectomy system
The Pantheris OCT system is a minimally invasive treatment for PAD in which a catheter-based device is used to remove plaque from a blood vessel. The lumivascular technology utilized in the system allows physicians to see from within the artery, enabling them to precisely remove plaque while leaving the healthy arterial structures intact. The system visualizes the artery without requiring ionizing radiation or toxic contrast medium (dye) injections, offering the potential to reduce physician, staff, and patient x-ray exposure, as well as minimize patient complications related to contrast exposure.
For more information, please visit www.avinger.com and www.healthtrustpg.com.